Past Events

The 2016 Alzheimer’s Disease Congress: 7th – 9th June 2016


London UK 7th- 9th June 2016

 This three day international academic congress will discuss current research and treatments being developed for Alzheimer’s Disease.

Agend       Abstract book

Topics for discussion include prediction and prevention strategies, vaccine development, drug discovery and care.

With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding Alzheimer’s Disease.


The abstract submissions deadline for oral presentation is 10th March 2016

The early registration deadline is 20th April 2016

The Poster submission deadline in 26th May 2016

The 2016 Alzheimer’s Disease Congress has an open abstract session:  Abstracts for oral or poster presentation can be submitted on any subject related to Alzheimer’s

This  event  is  now over

There  will be a meeting report in due course

For the follow up meeting please see

Talks include

Talk TitleSpeakerAffiliationCountry
Calcium, Memory and Alzheimer's diseaseSir Michael BerridgeThe Babraham InstituteUnited Kingdom
Drugs used in multiple pathologies, with stresses common to Alzheimers disease, offer candidate drugs and vaccine potential for Alzheimers diseaseProfessor Joan Smith SonnebornUniversity of WyomingUnited States
Targeting Nucleophilic Attack During Early Beta-Amyloid Peptide OligomerizationAdrien W. SchmidEcole Polytechnique Fédérale de Lausanne (EPFL)Switzerland
Neurophysiological vulnerability to aging associated with the Alzheimer’s risk variant in CLU geneDr Natalya PonomarevaResearch Center of NeurologyRussian Federation
The role of heparan sulfates in the amyloid pathology of Alzheimer diseaseCharlotte JendresenUniversity of Oslo and Oslo University HospitalNorway
Cholesterol's contribution to autophagy deficits in Alzheimer’s diseaseDr Anna ColellSpanish National Research Council (CSIC)Spain
Granulovacuolar degeneration, a neurodegenerative change that accompanies tau pathologyDr Christoph KöhlerUniversity of CologneGermany
Looking for the markers of asymptomatic stage of Alzheimer's disease in the retinaDr Slavica KranticUPMCFrance
Sigma-1 receptor ligand Fluvoxamine modulates production of amyloid beta peptides in vitro and is protective in J20 Alzheimer disease miceAssociate Professor John BJ KwokNeuroscience Research AustraliaAustralia
Probing dementia-associated disruption of neural circuits using neurophysiology and imaging in murine modelsProfessor Andrew RandallUniversity of Exeter Medical SchoolUnited Kingdom
Link between the modifiable risk factors of Alzheimer's disease and neuroinflammationDr Andis KlegerisUniversity of British Columbia Okanagan CampusCanada
Paradigm Shift: Semantic memory decline as a biomarker of preclinical Alzheimer’s diseaseProfessor Annalena VenneriUniversity of SheffieldUnited Kingdom
The regulation of metastable proteins in neurodegenerative diseasesRishika KundraUniversity of CambridgeUnited Kingdom
c-Abl signaling in Alzheimer's disease and other Neurodegenerative diseases: Projections for drugs searchingDr Alejandra Alvarez R, Pontificia Universidad Catolica de ChileChile
EEG biomarkers and profiling of AD mouse linesProfessor Bettina PlattUniversity of AberdeenUnited Kingdom
Potential therapeutic strategies of Cerebrolysin in Alzheimer's DiseaseDr Hari Shanker SharmUppsala UniversitySweden
Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysisDr Vasiliki OrgetaUniversity College LondonUnited Kingdom
Fighting Alzheimers Disease Professor Michal SchwartzThe Weizmann Institute of ScienceIsrael
Smell identification function in Alzheimer's diseaseDr Latha VelayudhanUniversity of LeicesterUnited Kingdom
Multiple roles of cholinergic neurons in the modulation of amyloid productionDr Jane RylettSchulich Medicine & DentistryCanada
Alpha2 adrenergic receptor as a novel target for Alzheimer's diseaseDr. Qin WangUniversity of Alabama at BirminghamUnited States
Associations of sorLA/SORL1 with Alzheimers diseaseDr. Olav Michael AnderseAarhus UniversityDenmark
Chaperoning Tau aggregationDr. Stefan RüdigerUtrecht UniversityNetherlands
The role of proliferating astrocytes in Alzheimer's diseaseDr Magdalena SastreImperial College LondonUnited Kingdom
Imaging-related biomarkers of cognitive decline in healthy controls.Dr. Panteleimon GiannakopoulosUniversity Hospitals of GenevaSwitzerland
Inflammation in Dementia with Lewy bodies and Alzheimer's Disease Dr Jay AminUniversity of SouthamptonUnited Kingdom
Dystrophic neurites are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation: the potential role of Aβ oligomersProfessor Robert Vassar, Northwestern University Interdepartmental NeuroscienceUnited States
What makes an amyloidogenic protein toxic? Dissecting the sequence - self-assembly -toxicity relationship for amyloid peptidesProfessor Louise SerpellUniversity of SussexUnited Kingdom
Loss of neuroprotective lipids and myelin as a key sensitizing factor in Alzheimer’s pathogenesis.Dr Anthony Simon DonUniversity of New South WalesAustralia
Alzheimer's Disease: a clinical viewpointDr Amit AroraUniversity Hospital of North StaffordshireUnited Kingdom
The role of Pb in AD pathogenesisDr. Yansheng DuIndiana University School of MedicineUnited States
Computational studies on the toxicity mechanisms of amyloid beta peptides aggregation in relation to Alzheimer's diseaseProfessor Chew Lock YueNanyang Technological UniversitySingapore
Type 2 diabetes mellitus accelerate tau pathology in nonhuman primateDr. Zhiming ZhangUniversity of Kentucky College of MedicineUnited States
Is GluN2B-NMDA receptor a good target in treating Alzheimer's disease?Professor Qiang ZhouPeking University Shenzhen Graduate SchoolChina
The drug therapy to increase stem cells for treatment of Alzheimer/s diseaseDr. Kiminobu SugayaUniversity of Central FloridaUnited States
The involvement of type-1 interferon signalling and resultant neuroinflammation Alzheimer's DiseaseDr. Peter CrackThe University of MelbourneAustralia
Characterizing Prodromal Alzheimer's Disease Using Multimodality ImagingDr. Val LoweMayo Clinic RochesterUnited States
PET imaging biomarkers in Alzheimer's DiseaseProfessor Karl HerholzUniversity of ManchesterUnited Kingdom
Where did we go wrong in the study of APP processingDr. Ming Chen,University of South FloridaUnited States
Good things in small packages: The molecular chaperone action of the small heat shock chaperone proteinsProfessor Heath EcroydUniversity of WollongongAustralia
Proteostasis Collapse and Protein Aggregation in Neurodegenerative DiseasesDr. Justin YerburyUniversity of WollongongAustralia
Predicting Progression to Mild Cognitive Impairment in Cognitively Unimpaired Individuals Using Neuroimaging BiomarkersDr. Cynthia M. StonningtonMayo Clinic College of MedicineUnited States
Biomedical nanotechnology and Alzheimer's. Can the disease be reversed?Professor Christopher WhiteleyNational Taiwan University of Science and TechnologyTaiwan

Advisory Board Members

Professor Jordan L Holtzman University of MinnesotaUnited States
Kaye ErvinUniversity of MelbourneAustralia
Dr Frank O. BastianLSU Agricultural CenterUnited States
Professor Sophia G. AntimisiarisUniversity of PatrasGreece
Professor Jane MortSouth Dakota State UniversityUnited States
Professor Urszula WojdaNencki Institute of Experimental BiologyPoland
Assistant Professor Myria PetrouUniversity of MichiganUnited States
Dr Mourad TayebiSurrey UniversityUnited Kingdom
Dr Philip LiuMass General Hospital and Harvard Medical SchoolUnited States
Professor Mark R WilsonUniversity of WollongongAustralia
Professor Qiang ZhouPeking University Shenzhen Graduate SchoolChina

CPD Credits

Related Past Event Agendas

thealzheimersdiseasecongress-agendaAlzheimers AgendaAgeing 2016 Agenda



Email:? enquiries [@]

Phone:?(+44) 020 3807 3712

Abstract and Poster Presentations

All abstracts accepted for oral presentation are also automatically accepted for poster presentation


Cancellation Policy

Join the conversation

Related past events




This is a closed event

Only participants who have registered are licensed to attend this event. This is for the protection and peace of mind of our speakers who are presenting unpublished work. We ask our participants not to share their screen with people who are not registered for the event and will fine those who do.

Latest Euroscicon Tweets

Error: You currently have access to a subset of Twitter API v2 endpoints and limited v1.1 endpoints (e.g. media post, oauth) only. If you need access to this endpoint, you may need a different access level. You can learn more here: